Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Income from Continuing Operations (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Income from Continuing Operations data on record, last reported at 7914000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 37.79% year-over-year to 7914000.0; the TTM value through Sep 2025 reached 47597000.0, up 13.33%, while the annual FY2024 figure was 56584000.0, 16.64% up from the prior year.
  • Income from Continuing Operations reached 7914000.0 in Q3 2025 per RANI's latest filing, up from 11224000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 5485000.0 in Q2 2021 and bottomed at 28700000.0 in Q3 2021.
  • Average Income from Continuing Operations over 5 years is 14356526.32, with a median of 14055000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: crashed 895.84% in 2021, then soared 42.78% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 13305000.0 in 2021, then dropped by 28.74% to 17129000.0 in 2022, then grew by 17.95% to 14055000.0 in 2023, then decreased by 11.85% to 15721000.0 in 2024, then skyrocketed by 49.66% to 7914000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 7914000.0 in Q3 2025, 11224000.0 in Q2 2025, and 12738000.0 in Q1 2025.